The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2018 | Precision medicine is the future of cancer treatment
Precision, or personalized, medicine has often been regarded as the future of cancer treatment. In this interview, Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, outlines the many benefits and uses of precision medicine, ranging from dissecting the biology of metastatic tumors to accumulating information for clinical trials. Dr Burris explains why he advocates for methods such as next-generation sequencing rather than PET scans and other less informative tests, and mentions some of the types of cancers that are already being investigated using this new precision medicine approach. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
